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This study assessed the ability of real-time reverse transcription–polymerase chain reaction (RT–PCR) analysis to detect
disseminated epithelial cells (DEC) in peripheral blood (PB) and bone marrow (BM) of patients with breast cancer (BC). Detection of
DEC in BM is an obvious choice in BC, but blood sampling is more convenient. The aim of this study was to evaluate whether the
detection of DEC in either PB or BM predicts overall survival (OS). Peripheral blood and BM samples were collected from 148
patients with primary (stage M0, n¼116/78%) and metastatic (stage Mþ, n¼32/21%) BC before the initiation of any local or
systemic treatment. Peripheral blood of healthy volunteers and BM of patients with a nonmalignant breast lesion or a haematological
malignancy served as the control group. Disseminated epithelial cells was detected by measuring relative gene expression (RGE) for
cytokeratin-19 (CK-19) and mammaglobin (MAM), using a quantitative RT–PCR detection method. The mean follow-up time was
786 days (þ/  487). Kaplan–Meier analysis was used for predicting OS. By taking the 95 percentile of the RGE of CK-19 (BM: 26.3
and PB: 58.7) of the control group as cutoff, elevated CK-19 expression was detected in 42 (28%) BM samples and in 22 (15%) PB
samples. Mammaglobin expression was elevated in 20% (both PB and BM) of the patients with BC. There was a 68% (CK-19) and
75% (MAM) concordance between PB and BM samples when classifying the results as either positive or negative. Patients with an
elevated CK-19 or MAM expression in the BM had a worse prognosis than patients without elevated expression levels (OS: log-rank
test, P¼0.0045 (CK-19) and P¼0.025 (MAM)). For PB survival analysis, no statistical significant difference was observed between
patients with or without elevated CK-19 or MAM expression (OS: log-rank test, P¼0.551 (CK-19) and P¼0.329 (MAM)). Separate
analyses of the M0 and Mþ patients revealed a marked difference in OS according to the BM CK-19 or MAM status in the Mþ
patient group, but in the M0 group, only MAM expression was a prognostic marker for OS. Disseminated epithelial cells, measured as
elevated CK-19 or MAM mRNA expression, could be detected in both PB and BM of patients with BC. Only the presence of DEC in
BM was highly predictive for OS. The occurrence of DEC in the BM is probably less time-dependent and may act as a filter for
circulating BC cells. The use of either larger volumes of PB or performing an enrichment step for circulating tumour in blood cells
might improve these results.
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Breast cancer (BC) remains an important public health problem. In
the 21st century, one out of nine women will develop BC. Most
patients present with stage I or II disease and at least up to 30–
40% of these patients will develop recurrent disease. These patients
are considered as having disseminated cancer cells at the time of
local treatment. Current guidelines for the adjuvant treatment in
lymph-node-negative BC patients have been shown to result in
overtreatment, with inherent disadvantages and even health risks
(Shapiro and Recht, 2001; Goldhirsh and Senn, 2003). Accurate
staging of patients diagnosed with BC is important to determine
the extent of disease and to plan appropriate therapies.
Molecular diagnostics have, for the first time, been integrated in
the revised tumour node metastasis (TNM) staging system for BC
in order to collect data on minimal disease in lymph nodes that
may affect treatment in the future (Singletary et al, 2002).
Analogous to the staging procedures in haematological malig-
nancies, detection of minimal disease in bone marrow (BM),
defined as single or clumped disseminated cancer cells, has been
suggested to be a more direct approach to select the metastasis-
prone patients among the ‘good prognosis group’, based on the
TNM staging (Braun and Pantel, 1998). Numerous studies have
elaborated on this concept by detecting disseminated epithelial
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scells (DEC), or transcripts of supposedly specific markers for
epithelial cells, in BM aspirates (Diel et al, 1996; Braun et al, 2000;
Janni et al, 2000; Gerber et al, 2001; Wiedswang et al, 2003). In
these studies, the BM status is considered as a mirror for the
efficacy of the metastatic process throughout the body, similar to
detection of cancer cells in lymph nodes. Also, the prognostic
relevance of DECs in BM is clearly demonstrated by a number of
large studies (Braun et al, 2000, 2005; Weinschenker et al, 2004).
The vast majority of these studies used immunocytochemistry for
cell detection. Currently, detection by polymerase chain reaction
(PCR) techniques is much less validated.
The detection of tumour cells in BM is an obvious choice in BC,
since a majority of patients will develop bone metastases once
dissemination has been detected clinically (Rubens, 1998).
Although BM aspiration is an acknowledged clinical method, it
remains cumbersome, especially if repetitive examinations are
considered. Peripheral blood (PB) is an other organ to evaluate a
patient for the presence of disseminated epithelial cancer cells,
although tumour cells in blood and tumour cells in BM do not
necessarily have the same metastatic potential. Repetitive sampling
of PB is accepted.
In this study, we attempted to quantify transcripts of one marker
considered relatively specific for epithelial cells, cytokeratin-19
(CK-19), and of a more breast-tissue-specific cell marker,
mammaglobin (MAM), in both the PB and BM of patients with
BC using quantitative real-time reverse transcription (RT)–PCR
according to the Taqman methodology. The hypothesis was that
the use of a quantitative technique would allow for the
discrimination between low amounts of epithelial-cell-related
present in the blood or BM of healthy individuals and the
presumably elevated amounts of tumour-cell-related transcripts
present in the blood or BM of advanced cancer patients, both
resulting in a ‘positive’ signal with nonquantitative techniques.
Cytokeratin-19 was chosen as it is expressed in the majority
of BCs (Bartek et al, 1986) and has been extensively used in
studies in this area (Slade et al, 1999; Smith et al, 2000; Aerts et al,
2001; Stathopoulou et al, 2003; Benoy et al, 2004; Ring et al, 2005).
Mammaglobin gene expression has previously been used to
detect circulating BC micometastases with no false-positives in
the control population (Zach et al, 1999; Grunewald et al, 2000;
Suchy et al, 2000; Leone et al, 2001; Silva et al, 2002;
Ring et al, 2005).
The aim of this study was to compare directly the detection rate
of DEC in blood and BM by a sensitive and specific real-time RT–
PCR method and to clarify their prognostic value. We investigated
the possibility of replacing BM aspiration by PB sampling for the
detection of isolated tumour cells. Therefore, this study is
conducted on simultaneously acquired blood and BM samples
from 148 patients with BC with stage I to IV disease before the
initiation of any local or systemic treatment.
PATIENTS AND METHODS
Patients and sample handling
Peripheral blood samples and BM aspirates were obtained from
148 patients with BC (age: 27–88 years), 116 patients with primary
disease (M0, 78%) and 32 patients with metastatic disease (Mþ,
21%). Samples were collected before surgery or implementation of
therapy and the Mþ patients had no previous treatment for
metastatic disease. All patients were treated in the General Hospital
Sint-Augustinus and follow-up data were obtained prospectively.
Clinical and histopathological data, therapy, relapse and survival
information from each patient were entered in a database. The
mean follow-up time was 786 days (s.d.: 487, median 855). All
analysis were conducted blind of the patients’ clinicopathological
status.
Peripheral blood samples from 37 healthy female volunteers
(age: 21–80 years) served as controls. A measure of 9ml of PB was
stored in EDTA-containing tubes (Becton Dickinson, Vacutainer
system, Belgium) and processed within 2h after sampling. To
avoid epithelial contamination by the skin during venipuncture,
the first 8ml of blood was discarded.
Bone marrow aspirates were taken under locale or general
anaesthesia. Bone marrow aspirates from 13 patients with a
nonmalignant breast lesion or a haematological malignancy served
as control patients (age: 25–79 years). A measure of 9ml of BM
was aspirated from the posterior iliac crest into syringes contain-
ing 5000IU heparin as anticoagulant. To avoid epithelial
contamination during aspiration, a small incision was made in
the skin and the first 2ml of BM was discarded. The BM aspirate
was transported to the lab within 30min. Mononuclear cells
(MNC) were isolated by density-gradient centrifugation through
Ficoll–Hypaque (Amersham Pharmacia Biotech, Sweden) and
washed twice with PBS. After centrifugation, the cell pellet was
resuspended in a guanidine isothiocyanate-containing buffer.
The patients were divided into two groups: without overt
metastasis (M0) and with metastasis (Mþ). The study protocol
was approved by the ethical committees of the Faculty of Medicine,
University of Antwerp, and of the General Hospital Sint-
Augustinus. All patients and volunteers signed a written informed
consent.
RNA isolation and cDNA synthesis
Total RNA was isolated from the blood, using the Qiagen Rneasy
Total Blood RNA Kit. From the BM MNC, total RNA was extracted
with the RNeasy midi kit (Qiagen, Germany). The exact volume of
blood and BM (range PB: 8–9ml; BM: 4–9ml), used for RNA
extraction and the exact elution volume (range 150–600ml) were
documented to enable the calculation of target mRNA concentra-
tion afterwards.
The concentration of RNA was measured spectrophotometri-
cally. All samples had an OD 260/280nm ratio 41.8. The RNA
integrity was tested on the Agilent 2100 Bioanalyzer. Only samples
lacking degradation on the electropherogram and with a good 28S/
18S ratio were analysed.
For the generation of first-strand cDNA, 2mg of total RNA
was reverse-transcribed in a final volume of 100ml with the
High-Capacity cDNA Archive Kit (Applied Biosystems, The
Netherlands).
PCR amplification
CK-19 and MAM mRNA expression was measured as described
before (Benoy et al, 2004). cDNA-specific CK-19 and hMAM
Taqmant primer and probe sets were developed using Primer
Express
s software. To avoid amplification of contaminating
genomic DNA, primers and probes were placed on different
exons. The forward primer of CK-19 (CCCGCGACTACAGCCAC
TA) is situated on exon 1, the probe (FAM-ACCATTGAGAACTC
CAGGATTGTCCTGCA-TAMRA) on exon 2 and the reverse primer
(CTCATGCGCAGAGCCTGTT) on exon 3. Reverse transcription–
polymerase chain reaction using this primer set resulted in a
163bp fragment. For hMAM, the forward primer (ATGAAGT
TGCTGATGGTCCTCAT) and the probe (FAM-CGGCCCTCTC
CCAGCACTGC-TAMRA) are located on exon 1 and the reverse
primer (GTCTTAGACACTTGTGGATTGATTGTCT) on exon 2.
The hMAM amplicon consists of 119bp. The nucleotide sequences
of the primers and probes were checked for their specificity in the
NCBI BLAST
s database.
All PCR reactions were performed on the ABI Prism 7700
Sequence Detection System (Applied Biosystems) using the
fluorescent Taqman methodology. The PCR cycle at which the
CK-19 and MAM expression in blood and bone marrow
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threshold (Ct).
A measure of 10ml of the reverse transcription volume was used
for each PCR reaction in a total volume of 50ml. Commercially
available primers and probe for b-actin mRNA were used for
normalisation (Applied Biosystems). This probe is labelled with a
VIC dye, and to avoid competition in the multiplex PCR reaction
tube, the concentrations of the primers are limited.
The CK-19 and MAM mRNA quantities were analysed in
triplicate and mean Ct levels were used for further analyses. Results
were normalised against b-actin and expressed in relation to a
calibrator sample. As described by Livak and Schmittgen (2001),
results per PCR reaction were expressed as relative gene expression
(RGE), using the delta–delta Ct method. The calibrator was
produced from the blood of a healthy volunteer spiked with 5
MDA-MB361 cells per 10
6 blood cells. The calibrator was given an
RGE value of 100. As we are only interested in the amount of CK-
19 or MAM expression per ml of sample, regardless of the amount
of white blood cells, RGE per PCR reaction was normalised
according to the following equation:
nRGE ¼ RGE
CRNAVRNA
Vext
1
CcDNAVPCR
where nRGE is the normalised RGE expressed as relative target
concentration per ml PB or BM (RGE per ml sample); RGE is the
relative gene expression of target determined by sequence detector
per PCR reaction; CRNA is the concentration of totalRNA extracted
per sample; VRNA is the elution volume of totalRNA obtained after
extraction, typically 300ml per Qiagen RNeasy Midi Extraction;
Vext is the volume of PB or BM extracted, typically 9ml; CcDNA
is the concentration cDNA, typically 2mg/100ml; and VPCR is the
volume of cDNA solution used for PCR amplification, typically
10ml.
Statistics
Data were analysed using the statistical software package SPSS
12.0. The Mann–Whitney U-test was used to validate differences in
gene expression of CK-19 and MAM between the control and
patient populations. Correlation analyses were validated by the
Spearman rho correlation test for continuous nonparametric
variables and by the kappa test for categorical variables (Landis
and Koch, 1977). Differences in positivity rates between blood and
BM samples were assessed using the McNemar test. The w
2 test and
linear-by-linear test were used to assess the relation between
patient characteristics and rates of positive samples.
Overall survival (OS) was calculated from the day of diagnosis
(sample take) until death or last follow-up, regardless of the cause
of death. Distance disease-free survival (DDFS) was calculated for
the M0 group from the day of diagnosis until relapse. Survival
curves were calculated for each group with Kaplan–Meier
estimates and compared with the log-rank test. Cox’s propor-
tional-hazards regression was used for univariate and multivariate
(stepwise backward elimination) analysis of prognostic impact of
relevant variables. P-values smaller than 0.05 were considered
statistically significant.
RESULTS
CK-19 and MAM mRNA expression in PB samples of
healthy volunteers and patients with BC
To determine the cutoff point for CK-19 mRNA and MAM mRNA
expression in blood, RGE was determined in 37 blood samples of
healthy volunteers (Table 1). In all these blood samples, CK-19
mRNA was measurable with a median nRGE of 26.5 (range: 0.4–
104). The cutoff value, determined as the 95 percentile of the CK-
19 nRGE values of healthy volunteers, was 58.7. Mammaglobin
(MAM) expression was measurable in four of the 37 control blood
samples. The cutoff level was set as 0.092 (95 percentile of the
normal MAM values).
Results for nRGE of CK-19 and MAM mRNA expression in PB
samples of patients with BC are summarised in Table 1.
The correlation between CK-19 and MAM expression is
illustrated in Figure 1A (Spearman rho¼0.199, P¼0.015). Nine
patients had an elevated expression of both CK-19 and MAM in
their blood, 13 samples had only an elevated CK-19 expression and
a normal MAM expression, whereas 20 patients showed an
elevated MAM expression with a normal CK-19 expression. In
all, 106 patients had both a normal CK-19 and MAM expression.
Significant differences in expression level of MAM were
observed between negative control samples, patients with non-
metastatic BC and patients with metastatic BC. For CK-19, only a
difference in expression level was observed between the negative
control group and the Mþ group (Mann–Whitney U-test;
Table 1).
CK-19 and MAM mRNA expression in BM
In none of the 13 negative control BM samples MAM expression
was measurable by RT–PCR. On the other hand, CK-19 mRNA
could be quantified in all control samples, with a median RGE of
9.94 (range 4–36) (Table 1). With the 95 percentile from the CK-19
RGE (26.3) of the negative control group as cutoff, 15 of the 32
(47%) BM aspirates from the Mþ patients had an increased CK-19
Table 1 RT–PCR results for the detection of disseminated epithelial
cells in different patient groups
PB_nCK
a PB_nMAM
b BM_nCK
c BM_nMAM
d
NC
e
N 37 37 13 13
Median 26.50 0 9.94 0
Minimum 0.37 0 4.12 0
Maximum 103.72 0.216 36.01 0
Cutoff 58.7 0.092 26.3 0
M0
f
N 116 116 116 116
Median 26.4867 0 12.0675 0
Minimum 2.58 0 1.15 0
Maximum 155.94 12.88 231368.22 1171.36
#pos (%) 14 (12) 16 (14) 27 (23) 18 (16)
P-value vs M+
M+
g
N 32 32 32 32
Median 34.2550 0.0592 24.7800 0
Minimum 2.30 0 2.47 0
Maximum 147.69 182.16 2150887.66 1588.40
#pos (%) 8 (25) 13 (40) 15 (47) 12 (38)
Mann–Whitney U-test
h
P-value NC vs M0 0.44 0.033 0.51 0.13
P-value NC vs M+ 0.047 o0.0001 0.04 0.012
P-value M0 vs M+ 0.15 0.002 0.004 0.002
BM¼bone marrow; CK-19¼cytokeratin-19; MAM¼mammaglobin; PB¼periph-
eral blood; RT–PCR¼reverse transcription–polymerase chain reaction.
aNorma-
lised relative gene expression of cytokeratin-19 mRNA in peripheral blood.
bNormalised relative gene expression of mammaglobin mRNA in peripheral blood.
cNormalised relative gene expression of cytokeratin-19 mRNA in bone marrow.
dNormalised relative gene expression of mammaglobin mRNA in bone marrow.
eNegative control patients.
fPatients with primary breast cancer without overt
metastasis.
gPatients with metastatic breast cancer.
hMann–Whitney U-test:
differences in CK-19 or MAM mRNA expression in peripheral blood or bone
marrow between the different subgroups of patients with breast cancer.
CK-19 and MAM expression in blood and bone marrow
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sexpression. MAM expression was measurable in 12 of the 32 (38%)
samples. Results for the M0 group are presented in Table 1.
The correlation between CK-19 and MAM expression is
illustrated in Figure 1B (Spearman rho¼0.254, P¼0.0019). In
total, 14 patients had an elevated expression of both CK-19 and
MAM in their BM, 28 samples had only an elevated CK-19
expression and a normal MAM expression, whereas 16 patients
showed an elevated MAM expression with a normal CK-19
expression. A total of 90 patients had both a normal CK-19 and
MAM expression.
A significant difference in CK-19 and MAM mRNA expression
in BM is observed between negative control samples or patients
with operable BC and patients with disseminated disease (Table 1).
Concordance of CK-19 and MAM expression in blood and
BM samples
A strong correlation was found for CK-19 and MAM nRGE in
blood and BM samples (CK-19: Spearman rho¼0.3, P¼0.0003,
95% confidence interval (CI)¼0.14–0.44/MAM: Spearman
rho¼0.25, P¼0.024, 95% CI¼0.09–0.40). When the different
patient groups were analysed separately, the correlation between
blood and BM was confirmed (except for MAM expression in the
M0 group) (data not shown).
In only 19% (eight of 42) of the patient samples with a BM CK-
19 RGE above the cutoff, CK-19 expression was also elevated in the
PB sample. On the other hand, 87% (92 of 106) of the patients with
normal CK-19 expression in the BM sample also had normal CK-19
expression in the PB (Table 2). Overall, there was 68% (100 of 148)
concordance between blood and BM for CK-19 mRNA positivity,
with a slight kappa value (0.07). According to the McNemar test,
there was a significant difference in positivity between blood and
BM CK-19 expression (P¼0.006).
For MAM expression, a concordance of 75% (111 of 148) was
found between blood and BM (Table 2). The kappa value for MAM
expression was fair (0.22) and there was no difference in positivity
according to the McNemar test (P¼1).
Relation of DEC in blood and BM with clinicopathological
parameters
Results of the w
2 test, to assess the relation between patient
characteristics and rates of positive samples for the presence of
DECs in blood and BM of patients with BC, are presented in
Table 3. No relation was found between the presence of DEC in
blood or BM and T stage, N stage, oestrogen receptor (ER)
hormone receptor status, histology, histological grade or meno-
pausal status. The presence of elevated CK-19 or MAM expression
in BM was correlated with PR hormone receptor status.
DEC and survival
During the observation period, 21 of the 148 patients with BC have
died. In the BM CK-19þ group, 11 of the 42 patients died,
compared with 10 of the 106 BM CK-19  group. When analysing
survival data according to the MAM expression in BM, seven of the
30 BM MAMþ patients died, compared with 14 of the 118 BM
MAM  patient group (Table 4). Kaplan–Meier survival analysis
demonstrates a markedly reduced OS among the BMþ patients
(OS: log-rank test, P¼0.0045 (CK-19) and P¼0.025 (MAM))
(Figure 2). Among women with an elevated CK-19 mRNA
expression in the BM, as compared with those with a normal
CK-19 expression, the relative risk of death was 3.26 (95% CI 1.38–
7.73, P¼0.007). The relative risk for patients with elevated MAM
mRNA expression in the BM was 2.72 (95% CI 1.10–6.75),
compared with those without MAM mRNA expression (Table 4).
Patients with an elevated CK-19 and MAM expression (double
phenotypes) have the worst prognosis (Figure 2 and Table 4).
In contrast to the BM status, presence of circulating tumour cells
in the PB had no impact on the OS of the patient (OS: log-rank test,
P¼0.551 (CK-19) and P¼0.329 (MAM)).
Separate analyses of the M0 and Mþ patients revealed a marked
difference in OS according to the BM CK-19 or MAM status in the
Mþ patient group, but in the M0 group, only MAM expression
was a prognostic marker for OS (OS: log-rank test, P¼0.125 (CK-
19) and P¼0.041 (MAM), P¼0.035 (double phenotypes)).
Survival analyses for DDFS were comparable with OS for these
M0 patient group (DDFS: log-rank test, P¼0.204 (CK-19) and
P¼0.063 (MAM), P¼0.049 (double phenotypes)).
Table 2 Comparison between blood and BM samples for the detection
of disseminated epithelial cells according to the relative gene expression of
CK-19 and/ or MAM
Number of patients CK-19 MAM
PB+BM+ 8 11
PB+BM  14 18
PB BM+ 34 19
PB BM  92 100
Concordance (%) 100/148 (68%) 111/148 (75%)
BM¼bone marrow; CK-19¼cytokeratin-19; MAM¼mammaglobin; PB¼peri-
pheral blood.
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Figure 1 Correlation between CK-19 and MAM relative gene
expression (nRGE) in (A) peripheral blood (PB) and (B) bone marrow
(BM).
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Following parameters were evaluated for OS: BM status, PB status,
menopausal status, tumour status, lymph node status, metastatic
status, hormone receptor status, histological grade, tumour
histology and Her2 status. On multivariate analysis, metastatic
stage, histological grade and BM CK-19 mRNA expression were
the only independent factors of poor prognosis. Results are
summarised in Table 5.
DISCUSSION
This study describes a sensitive method to quantify CK-19 and
MAM mRNA expression in blood and BM samples, using real-time
RT–PCR and the fluorescent Taqman assay. This mRNA is
supposed to be derived from disseminated tumour cells, perform-
ing critical steps of the metastatic cascade. In support of this
concept are the higher expression levels obtained in the blood and
BM of patients with advanced BC in this and other studies (Aerts
et al, 2001; Stathopoulou et al, 2003; Benoy et al, 2004; Slade et al,
2005).
Two distinct approaches are widely used to detect isolated
tumour cells: immunocytochemical (ICC)- and molecular biologi-
cal-based methods. Immunocytochemical is still the standard
method for tumour cell detection, but in the last years, there is a
rapid expansion in the application of molecular PCR-based
methods to detect isolated tumour cells in haematological fluids.
The problem of PCR analysis is the specificity and the
reproducibility of the different methods described in the literature.
The need for validation of the results in an independent validation
cohort is advisable.
CK-19 mRNA expression was measurable in PB of healthy
volunteers and in the BM of negative control patients. In order to
improve the specificity of the assay – a specificity that is negatively
affected by the high sensitivity of the RT–PCR technique –
establishing a cutoff was pursued instead of performing a negative
immunological preselection or another method to eliminate
fractions of nonepithelial blood cells that might express CK-19 at
low levels. The rationale was that the latter methods unavoidably
Table 3 Relation of DEC in blood and bone marrow of patients with operable breast cancer with clinicopathological parameters
All patients PB CK-19+patients PB MAM+patients BM CK-19+patients BM MAM+patients
Characteristic No. % No. % P No. % P No. % P No. % P
Menopausal status 0.744 0.775 0.298 0.436
Pre 37 25.5 5 13.5 8 21.6 8 21.6 6 16.2
Post 108 74.5 17 15.7 21 19.4 33 30.6 24 22.2
Unknown 3
M status 0.069 0.001 0.009 0.006
M0 116 78.4 14 12.1 16 13.8 27 23.3 18 15.5
M+ 32 21.6 8 25.0 13 40.6 15 46.9 12 37.5
Lymph node status 0.49 0.661 0.183 0.314
N0 51 34.5 9 17.6 11 21.6 11 21.6 8 15.7
N+ 97 65.5 13 13.4 18 18.6 31 32.0 22 22.7
Tumour status 0.611 0.981 0.718 0.444
T1T2 88 59.5 12 13.6 17 19.3 24 27.3 16 18.2
T3T4 60 40.5 10 16.7 12 20.0 18 30.0 14 23.3
Histology 0.126 0.144 0.627 0.642
Ductal 125 84.5 21 16.8 27 21.6 36 28.8 25 20.0
Lobular 21 14.2 1 4.8 2 9.5 6 28.6 4 19.0
Other 2 1.4 0 0.0 0 0.0 0 0.0 1 50.0
Histological grade 0.051 0.44 0.34 0.118
I 35 24.3 2 5.7 5 14.3 10 28.6 3 8.6
II 63 43.8 10 15.9 14 22.2 14 22.2 16 25.4
III 46 31.9 10 21.7 10 21.7 17 37.0 11 23.9
Unknown 4
ER status 0.291 0.354 0.056 0.787
Negative 46 31.3 9 19.6 7 15.2 18 39.1 10 21.7
Positive 101 68.7 13 12.9 22 21.8 24 23.8 20 19.8
Unknown 1
PR status 0.158 0.717 0.028 0.026
Negative 67 45.3 13 19.4 14 20.9 25 37.3 19 28.4
Positive 81 54.7 9 11.1 15 18.5 17 21.0 11 13.6
Her2 expression 0.001 0.221 0.459 0.085
Negative 126 86.3 14 11.1 23 18.3 34 27.0 23 18.3
Positive 20 13.7 8 40.0 6 30.0 7 35.0 7 35.0
Unknown 2
BM¼bone marrow; CK-19¼cytokeratin-19; DEC¼disseminated epithelial cells; ER¼oestrogen receptor; MAM¼mammaglobin; PB¼peripheral blood; PR¼progesterone
receptor. Statistically significant relations are present in bold.
CK-19 and MAM expression in blood and bone marrow
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was predefined as the 95th percentile value of CK-19 mRNA
expression measured in the control population. The aim was to
design a sensitive tool to detect ongoing metastasis, even in
patients with operable disease, in order to minimise false-
negativity. By adopting more stringent criteria like changing the
cutoff to even higher than 95% of the control population (eg
maximum value of the control population þ2s.d.), survival
analysis for positive BM status will not change. For blood, only one
patient will be positive for the presence of circulating tumour cells,
which makes survival analysis meaningless.
Also, MAM mRNA expression was determined quantitatively in
blood and BM samples from patients with BC. In contrast to the
studies of Zach, Suchy, Corradini, Silva and Zehenter (Zach et al,
1999; Suchy et al, 2000; Corradini et al, 2001; Silva et al, 2002;
Zehentner et al, 2004), MAM mRNA could be amplified in four of
the 37 PB samples of the healthy control population. Amplification
of MAM mRNA in these four blood samples was only measurable
in one of the three replicates and with a CT value around the
detection limit of the PCR reaction (CT around 40 cycles) and is the
result of the high sensitivity of the methodology. Therefore,
analogous to the CK-19 mRNA expression, a cutoff value was
calculated.
In our study, we observed higher detection rates of DEC in BM
samples (CK-19: 28%) than in PB samples (CK-19: 15%) of patients
with BC. This is in agreement with several other studies
(Schoenfeld et al, 1997; Slade et al, 1999; Berois et al, 2000;
Stathopoulou et al, 2002; Ismail et al, 2004; Pierga et al, 2004), all
of whom demonstrate that BM is more likely to be positive than PB
for the presence of DEC (Table 4). Cancer cells may be
intermittently shed into the bloodstream, which could result in a
sampling error if a single-point sampling is evaluated. The
occurrence of DEC in the BM of BC patients is probably less
time-dependent and may act as a filter for circulating BC cells.
Classifying the results as negative or positive for the presence of
DEC, we retained with real-time RT–PCR analysis a concordance
between blood and BM samples for CK-19 expression of 68% and
for MAM expression of 75%. These results are consistent with the
findings of the other groups (Table 6). Statistically, no association
is found between CK-19 expression in blood and in that BM. It is
not yet clear whether all circulating tumour cells in PB can
establish tumours at other sites.
During the observation period with a mean of 786 days, 21 of the
148 patients have died. According to the survival analysis of this
group of 148 patients with BC, the presence of DEC in the BM and
not in PB is associated with poor prognosis. As the observation
period is relatively short when analysing only OS data for the M0
patient group, MAM expression or double phenotypes remain(s) a
prognostic marker, but there is a trend towards a significant
difference in survival in favour of patients who were CK-19  in the
BM.
Our results confirm the survival analyses of the group of
Wiedswang et al (2005), leading to the conclusion that the
detection of DEC in PB is quantitatively markedly different from,
and prognostically inferior to, the detection of DEC in BM. Pierga
et al (2004) concluded that the clinical value of circulating
epithelial cells has yet to be established. In their study, the
presence of tumour cells in the BM appears to be more predictive
of relapse than the presence of tumour cells in PB. The use
of larger volumes of PB or performing an enrichment step
for circulating tumour cells may be a better alternative. The
recent studies of Christofanilli seem to be promising: patients
with metastatic BC who have more than five circulating tumour
cells after enrichment in 7.5ml blood have a worse prognosis
than patients with less than five cells (Cristofanilli et al, 2004,
2005).
No correlation is observed between the presence of DEC in
blood or BM and conventional pathological markers such as
tumour size, lymph node status, ER hormone receptor status,
histology or Her2 status. These results are in agreement with the
studies of Braun and Schindlbeck, where established pathological
parameters did not predict the presence of ICC-detected CKþ in
BM samples (Braun et al, 2000; Schindlbeck et al, 2004). However,
in the meta-analysis of Weinschenker, a direct correlation was
observed between ICC BM positivity and the primary tumour’s
presence with expression of ER, large size and higher histologic
grade (Weinschenker et al, 2004). In the study of Pierga et al, the
presence of ICC CKþ cells in blood in patients with operable
disease was correlated with negative ER and nodal involvement.
The presence of ICC CKþ cells in the BM in these patients
was correlated with premenopausal status, Oestrogen-negative
tumours and clinical tumour size (Pierga et al, 2004). Lack of
correlation between expression of MAM mRNA in PB and known
prognostic factors for BC was also described by Lin et al (2003),
who used a conventional qualitative RT–PCR detection method.
In conclusion, we have developed a molecular method to
quantify CK-19 mRNA and MAM mRNA in PB and BM with high
sensitivity. By adopting a cutoff level of expression, a significant
difference between CK-19 mRNA load of the blood and BM of
healthy volunteers and of metastatic BC was found.
Bone marrow is more likely to be positive than PB for the
presence of DEC and independently predicts OS. The prognostic
value of BM involvement is also clearly demonstrated by a number
of large studies (Braun et al, 2000, 2003, 2005; Gebauer et al, 2001;
Gerber et al, 2001), which is less well established for blood
(Cristofanilli et al, 2004, 2005). Enrichment of circulating tumour
cells may be more promising. As repetitive sampling of blood is
more feasible than BM aspiration, detection of circulating
epithelial cells in blood would constitute a possible alternative or
complement to BM surveillance.
Table 4 Results of univariate analysis (Cox’s regression) for overall
survival in patients with breast cancer
All patients
No of patients who
died/total no.
Relative risk of
death (95% CI) P-value
BM CK-19
+ 11/42 3.26 (1.38–7.73) 0.007
  10/106 1
BM MAM
+ 7/30 2.72 (1.10–6.75) 0.031
  14/118 1
BM MAM and CK
+/+ 6/14 6.15 (2.16–17.45) 0.001
+/  or  /+ 6/44 1.68 (0.6–4.73) 0.325
 /  9/90 1
PB CK-19
+ 3/22 1.45 (0.43–4.94) 0.553
  18/126 1
PB MAM
+ 5/29 1.65 (0.60–4.52) 0.334
  16/119 1
PB MAM and CK
+/+ 2/9 4.04 (0.9–18.11) 0.068
+/  or  /+ 4/33 0.96 (0.32–2.91) 0.948
 /  15/106 1
BM¼bone marrow; CI¼confidence interval; CK-19¼cytokeratin-19;
MAM¼mammaglobin.
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Figure 2 Kaplan–Meier curves of overall survival of patients with breast cancer according to the presence or absence of disseminated epithelial cell in
bone marrow (BMþ or BM ) (curves A, C and E) or in peripheral blood (PBþ or PB ) (curves B, D and F) and according to cytokeratin-19 (CK-19)
(curves A, B, E and F) or mammaglobin expression (MAM) (curves C, D, E and F).
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